{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T06:08:34Z","timestamp":1773814114256,"version":"3.50.1"},"reference-count":0,"publisher":"Opast Group LLC","issue":"01","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Clin Exp Immunol"],"abstract":"<jats:p>Traumatic brain injury (TBI) is an acute disorder with prolonged complexities that affirm to be the leading cause of\ndeaths and disabilities in US. The pathophysiology of TBI comprises of multiple complex processes. An impactful insult\nresults in tissue damage, neuroinflammation, impaired cerebral blood flow, BBB disruption, and demyelination, leading\nto neurodegeneration and functional impairments. There are no specific treatments for TBI. Recent studies highlight the\npotential efficacy of the following benzoates for attenuating TBI pathologies in rodents:\n\u2022 Sodium benzoate, a metabolite of cinnamon, a widely used food additive and a Food and Drug Administration\n(FDA)-approved drug for glycine encephalopathy\n\u2022 Glyceryl tribenzoate, FDA-approved flavoring element being used in food and food packing productions\nIn this review, we have made a genuine attempt to evaluate the significance of these two benzoates as prospective\ntherapeutic options for TBI.<\/jats:p>","DOI":"10.33140\/jcei.11.01.02","type":"journal-article","created":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T05:14:43Z","timestamp":1773810883000},"page":"01-10","source":"Crossref","is-referenced-by-count":0,"title":["Benzoate Drugs for Traumatic Brain Injury"],"prefix":"10.33140","volume":"11","author":[{"given":"Swarupa","family":"Pahan","sequence":"first","affiliation":[{"name":"Division of Research and Development, Jesse Brown Veterans Affairs Medical Center, Chicago, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kalipada","family":"Pahan","sequence":"additional","affiliation":[{"name":"Division of Research and Development, Jesse Brown Veterans Affairs Medical Center, Chicago, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"18493","published-online":{"date-parts":[[2026,3,14]]},"container-title":["Journal of Clinical &amp; Experimental Immunology"],"original-title":["Benzoate Drugs for Traumatic Brain Injury"],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T05:14:44Z","timestamp":1773810884000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.opastpublishers.com\/open-access-articles\/benzoate-drugs-for-traumatic-brain-injury-10433.html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,14]]},"references-count":0,"journal-issue":{"issue":"01","published-online":{"date-parts":[[2026,3,14]]}},"URL":"https:\/\/doi.org\/10.33140\/jcei.11.01.02","relation":{},"ISSN":["2475-6296"],"issn-type":[{"value":"2475-6296","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,14]]}}}